| Dr Derek Douglas Kane, MD MS | |
|
310 N 10th St, Bismarck, ND 58501-4516 | |
| (701) 877-2040 | |
| (701) 639-2465 |
| Full Name | Dr Derek Douglas Kane |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 20 Years |
| Location | 310 N 10th St, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508942897 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 48821-020 (Wisconsin) | Secondary |
| 208600000X | Surgery | 11265 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi St Alexius Health | Bismarck, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Infinity Medical Management Llc | 4183020555 | 12 |
News Archive
GNC Holdings, Inc., a leading global specialty retailer of health and wellness products, today reported its financial results for the quarter and year-to-date periods ended September 30, 2014.
AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.
Celerion, the premier provider of innovative early stage clinical research solutions, announces the launch of a new Hybrid Phase I/ ECG Core lab. The Hybrid Phase I/ ECG Core lab provides highly automated ECG analysis for Celerion's global Phase I clinical network. Celerion's highly automated approach employs cutting-edge technology to perform automated measurement of ECG recordings, thereby minimizing cardiologist review and providing clients with faster access to data.
A new report on non-invasive prenatal testing by the UK's Nuffield Council on Bioethics expresses concerns about the way the test is being sold by private providers.
More than three decades of research on Alzheimer's disease have not produced any major treatment advances for those with the disorder, according to a UCLA expert who has studied the biochemistry of the brain and Alzheimer's for nearly 30 years.
› Verified 5 days ago
| Entity Name | Infinity Medical Management Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366116287 PECOS PAC ID: 4183020555 Enrollment ID: O20210909003186 |
News Archive
GNC Holdings, Inc., a leading global specialty retailer of health and wellness products, today reported its financial results for the quarter and year-to-date periods ended September 30, 2014.
AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.
Celerion, the premier provider of innovative early stage clinical research solutions, announces the launch of a new Hybrid Phase I/ ECG Core lab. The Hybrid Phase I/ ECG Core lab provides highly automated ECG analysis for Celerion's global Phase I clinical network. Celerion's highly automated approach employs cutting-edge technology to perform automated measurement of ECG recordings, thereby minimizing cardiologist review and providing clients with faster access to data.
A new report on non-invasive prenatal testing by the UK's Nuffield Council on Bioethics expresses concerns about the way the test is being sold by private providers.
More than three decades of research on Alzheimer's disease have not produced any major treatment advances for those with the disorder, according to a UCLA expert who has studied the biochemistry of the brain and Alzheimer's for nearly 30 years.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Derek Douglas Kane, MD MS 301 N. 10th St, Bismarck, ND 58501 Ph: (701) 877-2040 | Dr Derek Douglas Kane, MD MS 310 N 10th St, Bismarck, ND 58501-4516 Ph: (701) 877-2040 |
News Archive
GNC Holdings, Inc., a leading global specialty retailer of health and wellness products, today reported its financial results for the quarter and year-to-date periods ended September 30, 2014.
AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.
Celerion, the premier provider of innovative early stage clinical research solutions, announces the launch of a new Hybrid Phase I/ ECG Core lab. The Hybrid Phase I/ ECG Core lab provides highly automated ECG analysis for Celerion's global Phase I clinical network. Celerion's highly automated approach employs cutting-edge technology to perform automated measurement of ECG recordings, thereby minimizing cardiologist review and providing clients with faster access to data.
A new report on non-invasive prenatal testing by the UK's Nuffield Council on Bioethics expresses concerns about the way the test is being sold by private providers.
More than three decades of research on Alzheimer's disease have not produced any major treatment advances for those with the disorder, according to a UCLA expert who has studied the biochemistry of the brain and Alzheimer's for nearly 30 years.
› Verified 5 days ago
Dr. Joshua John Knudson, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-5422 | |
Michael Brandon Huck, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-5383 | |
Dr. Steven K Hamar, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 401 N 9th St, Bismarck, ND 58501 Phone: 701-530-6000 Fax: 701-530-6430 | |
Dr. William E Altringer, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 401 N 9th St, Bismarck, ND 58501 Phone: 701-530-6000 Fax: 701-530-6430 | |
D'arcy Adaire Honeycutt, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 810 E Rosser Ave, Suite 303, Bismarck, ND 58501 Phone: 701-530-8450 Fax: 701-530-8457 | |
Dr. George H Hilts Iii, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 200 S 5th St, Bismarck, ND 58504 Phone: 701-222-3937 Fax: 701-222-8805 | |
Josephat Gichuhi Ngatia, M.D Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 |